# DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Source: https://onco.cc/trials/nct06276283/  
OnCo record `nct06276283` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sunvozertinib and Bevacizumab in non-small-cell lung cancer, run by Dizal Pharmaceuticals, now recruiting.

## Summary

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) is a phase 2 interventional study registered as NCT06276283 by Dizal Pharmaceuticals, with 60 participants planned, started 2023-02-15 and due to reach its primary completion in 2025-12-31. Interventions recorded: DZD9008 plus Bevacizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06276283
- Phase: 2
- Setting: A Phase II, Single Arm, Multicenter Study to Assess the Safety, Tolerability and Anti-Tumor Efficacy of DZD9008 With Bevacizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Mutations (WU-KONG29)
- Sponsor: Dizal Pharmaceuticals
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06276283: https://clinicaltrials.gov/study/NCT06276283

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Sunvozertinib](https://onco.cc/drugs/sunvozertinib/)
- companies: [Dizal Pharmaceutical](https://onco.cc/companies/dizal/)

---
JSON: https://onco.cc/api/v1/entities/nct06276283.json